ADE (Incidence %)

Burzynski et al. 2014 Antineoplastons

[15] Lashford et al. 2002 Temozolomide

[16] Dreyer et al. 2003 Idarubicin

[17] Warren et al. 2006 Lobradimil and Carboplatin

[18] Fouladi et al. 2007 Tipifarnib

[19] Gururangan et al. 2010 Bevacizumab and Irinotecan

Hypokalemia

1

Hypernatremia

11

1

Fatigue

1

7

Thrombocytopenia

7

53

42

15

13

Neutropenia

5

82

49

18

Leukopenia

5

15

Lymphopenia

4

Anemia

12

4

Nausea

2

3

Vomiting

2

2

2

Anorexia

<1

3

Infection

16

5

Sepsis

2

3

Pneumonia

2

2

Fever

1

Neuropathy

<1

2

Cerebral ischemia

2

7

Hemorrhage

2

Hypertension

1

27

Cardiotoxicity

1

13

Nephrotoxicity

1

2

Ototoxicity

2

Ocular toxicity

1

Stomatitis

1

Pruritus

1

Altered mental status

1

Seizures

<1

2

2

Headache

5

1

Pain

<1

2

1

Hepatotoxicity

13

Hypermagnesemia

1

Weight loss

1

Syncope

2

1

Lipase

1